Analysts expect CVS Health Corp (NYSE:CVS) to report earnings per share of $1.70 for the current fiscal quarter, according to Zacks Investment Research. Twenty Four analysts have provided estimates for CVS Health’s earnings, with estimates ranging from $1.53 to $1.79. CVS Health reported earnings per share of $1.73 during the same quarter last year, which would suggest a negative year over year growth rate of 1.7%. The company is expected to report its next earnings results on Tuesday, November 5th.

On average, analysts expect that CVS Health will report full-year earnings of $6.90 per share for the current financial year, with EPS estimates ranging from $6.76 to $7.00. For the next year, analysts expect that the company will post earnings of $7.15 per share, with EPS estimates ranging from $6.90 to $7.40. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for CVS Health.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.70 by $0.19. The company had revenue of $63.43 billion for the quarter, compared to analyst estimates of $62.66 billion. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. CVS Health’s revenue for the quarter was up 35.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.69 EPS.

CVS has been the topic of a number of analyst reports. Evercore ISI set a $63.00 price target on CVS Health and gave the company a “buy” rating in a research report on Wednesday, August 7th. UBS Group dropped their price objective on CVS Health from $74.00 to $67.00 and set a “sell” rating on the stock in a report on Thursday, May 2nd. BMO Capital Markets set a $63.00 price objective on CVS Health and gave the company a “hold” rating in a report on Friday, May 3rd. Citigroup increased their price objective on CVS Health from $68.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Credit Suisse Group downgraded CVS Health from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $73.00 to $61.00 in a report on Monday, April 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. CVS Health currently has an average rating of “Buy” and an average target price of $75.14.

CVS stock traded up $0.09 during mid-day trading on Wednesday, reaching $61.65. The company had a trading volume of 9,354,563 shares, compared to its average volume of 11,176,493. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.64 and a current ratio of 0.95. The company has a market capitalization of $80.18 billion, a price-to-earnings ratio of 8.71, a price-to-earnings-growth ratio of 1.32 and a beta of 0.90. The firm has a fifty day simple moving average of $57.08 and a 200 day simple moving average of $56.37. CVS Health has a fifty-two week low of $51.72 and a fifty-two week high of $82.15.

The company also recently declared a quarterly dividend, which was paid on Friday, August 2nd. Investors of record on Thursday, July 25th were paid a dividend of $0.50 per share. The ex-dividend date was Wednesday, July 24th. This represents a $2.00 dividend on an annualized basis and a yield of 3.24%. CVS Health’s dividend payout ratio is presently 28.25%.

Large investors have recently added to or reduced their stakes in the stock. Bay Harbor Wealth Management LLC grew its stake in CVS Health by 1,871.4% during the 1st quarter. Bay Harbor Wealth Management LLC now owns 552 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 524 shares during the last quarter. Centaurus Financial Inc. grew its stake in CVS Health by 570.8% during the 1st quarter. Centaurus Financial Inc. now owns 1,630 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 1,387 shares during the last quarter. Manchester Financial Inc. purchased a new position in CVS Health during the 2nd quarter worth approximately $31,000. Hudock Capital Group LLC grew its stake in CVS Health by 54.0% during the 2nd quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 202 shares during the last quarter. Finally, Executive Wealth Management LLC grew its stake in CVS Health by 62.4% during the 2nd quarter. Executive Wealth Management LLC now owns 565 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 217 shares during the last quarter. Hedge funds and other institutional investors own 75.20% of the company’s stock.

About CVS Health

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Read More: What is Green Investing?

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.